臓器チップ市場- 世界および地域別分析：オファリング別、臓器タイプ別、用途別、エンドユーザー別、国別：分析と予測（2024年～2033年）

世界の臓器チップの市場規模は、2023年の1億990万米ドルから2033年には35億9,630万米ドルに達すると予測され、予測期間の2024年～2033年のCAGRは42.09%になると予測されています。

世界の臓器チップ市場の成長を促進する主な要因には、創薬、毒性試験、マイクロ流体工学の分野における継続的な技術進歩が含まれます。組織工学、マイクロ流体工学、細胞生物学の組み合わせは、マイクロエンジニアリングによる臓器チップ（OOC）プラットフォームの開発に貢献しています。莫大な研究開発投資と政府機関やOOC参入企業との協力がさらに市場成長に寄与しています。

世界の臓器チップ市場は、機器システム、チップやマイクロ流体デバイス、消耗品、ソフトウェアやデータ分析ツールなどの製品とサービス製品、および肝臓オンチップ、腎臓オンチップ、肺オンチップ、心臓オンチップ、脳オンチップ、その他の臓器チップなどの臓器タイプで構成されます。

臓器チップ市場では、医薬品開発や個別化医療における高度なソリューションの必要性から、主要企業間のパートナーシップが顕著に増加しています。各社が互いの技術的専門知識や市場でのプレゼンスを活用することを目的としているため、協力的な取り組みが普及しています。例えば、製薬大手とバイオテクノロジー企業との提携は、革新的な臓器チップ技術の主要な医薬品検査プロセスへの統合を促進しています。こうした提携は、研究能力を高めるだけでなく、臓器チッププラットフォームの商業化を加速させています。

臓器チップ市場は投資と資金調達の急増を経験しており、これはこの技術が医薬品開発と個別化医療に革命を起こす可能性があるという確信の高まりを反映しています。ベンチャーキャピタル、非公開会社、大手製薬会社は、臓器チッププラットフォームの開発と商業化を支援するため、ますます多額の資金を投入するようになっています。このような資本の流入により、新興企業も既存企業も研究開発を加速させ、技術力を拡大し、革新的なソリューションをより迅速に市場に投入できるようになっています。

当レポートでは、世界の臓器チップ市場について調査し、市場の概要とともに、オファリング別、臓器タイプ別、用途別、エンドユーザー別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

範囲と定義

第1章 市場

• 動向：現在および将来の影響評価
• R&Dレビュー
• サプライチェーンの概要
• 規制状況
  • 米国の規制枠組み
  • 欧州の規制枠組み
  • 日本の規制枠組み
  • 中国の規制枠組み
  • その他の国の規制枠組み
• 市場力学：概要
  • 市場の促進要因
  • 市場の課題
  • 市場の機会

第2章 用途

• 用途のセグメンテーション
• 用途の概要
• 世界の臓器チップ市場（用途別）
• 世界の臓器チップ市場（エンドユーザー別）

第3章 製品

• 製品セグメンテーション
• 製品概要
• 世界の臓器チップ市場（オファリング別）
• 世界の臓器チップ市場（臓器タイプ別）

第4章 地域

• 地域別概要
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第5章 市場- 競合ベンチマーキングと企業プロファイル

• 今後の見通し
  • Emulate, Inc.
  • Mimetas B.V.
  • Kirkstall Ltd.
  • Numa BioSciences
  • AxoSim
  • BICO Group AB
  • CN Bio Innovations Ltd.
  • SynVivo, Inc.
  • BEOnchip
  • The Charles Stark Draper Laboratory, Inc.
  • TissUse GmbH
  • InSphero
  • Obatala Sciences
  • Hesperos, Inc.
  • Cherry Biotech

第6章 調査手法

List of Figures

• Figure 1 Global Organ on Chip Market (by Region), $Million, 2023, 2027, and 2033
• Figure 2 Global Organ-on-Chip Market (by Application), $Million, 2023 and 2033
• Figure 3 Global Organ-on-Chip Market (by Offering), $Million, 2023 and 2033
• Figure 4 Global Organ-on-Chip Market (by Organ Type), $Million, 2023 and 2033
• Figure 5 Global Organ-on-Chip Market (by End User), $Million, 2023 and 2033
• Figure 6 Key Events to Keep Track of in the Organ-on-Chip Market
• Figure 7 Global Organ-on-Chip Market, Patent Analysis (by Year), January 2020-April 2024
• Figure 8 Global Organ-on-Chip Market, Patent Analysis (by Country), January 2020-April 2024
• Figure 9 Supply Chain and Risks within the Supply Chain
• Figure 10 Global Organ-on-Chip Market, Value Chain Analysis
• Figure 11 Global Organ-on-Chip Market, Market Map
• Figure 12 Impact Analysis of Market Navigating Factors, 2022-2033
• Figure 13 Articles Published on Increasing Use of Organ-on-Chip from 2013-2024
• Figure 14 U.S. Organ-on-Chip Market, $Million, 2023-2033
• Figure 15 Canada Organ-on-Chip Market, $Million, 2023-2033
• Figure 16 U.K. Organ-on-Chip Market, $Million, 2023-2033
• Figure 17 Germany Organ-on-Chip Market, $Million, 2023-2033
• Figure 18 France Organ-on-Chip Market, $Million, 2023-2033
• Figure 19 Italy Organ-on-Chip Market, $Million, 2023-2033
• Figure 20 Spain Organ-on-Chip Market, $Million, 2023-2033
• Figure 21 Rest-of-Europe Organ-on-Chip Market, $Million, 2023-2033
• Figure 22 China Organ-on-Chip Market, $Million, 2023-2033
• Figure 23 Japan Organ-on-Chip Market, $Million, 2023-2033
• Figure 24 India Organ-on-Chip Market, $Million, 2023-2033
• Figure 25 South Korea Organ-on-Chip Market, $Million, 2023-2033
• Figure 26 Rest-of-Asia-Pacific Organ-on-Chip Market, $Million, 2023-2033
• Figure 27 Brazil Organ-on-Chip Market, $Million, 2023-2033
• Figure 28 Mexico Organ-on-Chip Market, $Million, 2023-2033
• Figure 29 Rest-of-Latin America Organ-on-Chip Market, $Million, 2023-2033
• Figure 30 Strategic Initiatives, January 2021-April 2024
• Figure 31 Share of Strategic Initiatives, January 2021-April 2024
• Figure 32 Data Triangulation
• Figure 33 Top-Down and Bottom-Up Approach
• Figure 34 Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Opportunities across Regions
• Table 3: Key Trends, Impact Analysis
• Table 4: Global Organ-on-Chip Market, Partnerships and Collaborations
• Table 5: Global Organ-on-chip Market, Key Investments
• Table 6: Organ-on-Chip Market, Regulatory Landscape in Europe
• Table 7: Global Organ-on-Chip Market, New Offerings
• Table 8: Global Organ-on-Chip Market (by Application), $Million, 2023-2033
• Table 9: Global Organ-on-Chip Market (by End User), $Million, 2023-2033
• Table 10: Global Organ-on-Chip Market (by Offering), $Million, 2023-2033
• Table 11: Global Organ-on-Chip Market (by Organ Type), $Million, 2023-2033
• Table 12: Global Organ-on-Chip Market (by Region), $Million, 2023-2033
• Table 13: North America Organ-on-Chip Market (by Application), $Million, 2023-2033
• Table 14: North America Organ-on-Chip Market (by End User), $Million, 2023-2033
• Table 15: North America Organ-on-Chip Market (by Offering), $Million, 2023-2033
• Table 16: North America Organ-on-Chip Market (by Organ Type), $Million, 2023-2033
• Table 17: Europe Organ-on-Chip Market (by Application), $Million, 2023-2033
• Table 18: Europe Organ-on-Chip Market (by End User), $Million, 2023-2033
• Table 19: Europe Organ-on-Chip Market (by Offering), $Million, 2023-2033
• Table 20: Europe Organ-on-Chip Market (by Organ Type), $Million, 2023-2033
• Table 21: Asia-Pacific Organ-on-Chip Market (by Application), $Million, 2023-2033
• Table 22: Asia-Pacific Organ-on-Chip Market (by End User), $Million, 2023-2033
• Table 23: Asia-Pacific Organ-on-Chip Market (by Offering), $Million, 2023-2033
• Table 24: Asia-Pacific Organ-on-Chip Market (by Organ Type), $Million, 2023-2033
• Table 25: Latin America Organ-on-Chip Market (by Application), $Million, 2023-2033
• Table 26: Latin America Organ-on-Chip Market (by End User), $Million, 2023-2033
• Table 27: Latin America Organ-on-Chip Market (by Offering), $Million, 2023-2033
• Table 28: Latin America Organ-on-Chip Market (by Organ Type), $Million, 2023-2033
• Table 29: Middle East and Africa Organ-on-Chip Market (by Application), $Million, 2023-2033
• Table 30: Middle East and Africa Organ-on-Chip Market (by End User), $Million, 2023-2033
• Table 31: Middle East and Africa Organ-on-Chip Market (by Offering), $Million, 2023-2033
• Table 32: Middle East and Africa Organ-on-Chip Market (by Organ Type), $Million, 2023-2033
• Table 33: Global Organ-on-Chip Market, Company Share, 2023

Introduction to the Organ-on-Chip Market

The global organ-on-chip market is projected to reach $3,596.3 million by 2033 from $109.9 million in 2023, growing at a CAGR of 42.09% during the forecast period 2024-2033. The key factors driving the growth of the global organ-on-chip market include continuous technological advancements in the fields of drug discovery, toxicity testing, and microfluidics. The combination of tissue engineering, microfluidics, and cell biology has contributed to the development of a micro-engineered organ-on-chip (OOC) platform. Huge R&D investments and collaboration with government agencies and OOC players are further contributing to the market growth.

Market Introduction

The global organ-on-chip market consists of products and services products such as instrument systems, chips or microfluidic devices, consumables, and software and data analysis tools, as well as organ types that include liver-on-a-chip, kidney-on-a-chip, lung-on-a-chip, heart-on-a-chip, brain-on-a- chip, and other organ-on-chip.

Impact Analysis:

The organ-on-chip market has made an impact in the following ways:

Increasing Partnerships among Players: The organ-on-chip market has been witnessing a notable increase in partnerships among key players, driven by the need for advanced solutions in drug development and personalized medicine. Collaborative efforts have become more prevalent as companies aim to leverage each other's technological expertise and market presence. For instance, partnerships between pharmaceutical giants and biotech firms are facilitating the integration of innovative organ-on-chip technologies into mainstream drug testing processes. These alliances are not only enhancing research capabilities but also accelerating the commercialization of organ-on-chip platforms.

Increasing Investment and Funding for Organ-on-Chip Technologies: The organ-on-chip market has been experiencing a surge in investment and funding, reflecting growing confidence in the technology's potential to revolutionize drug development and personalized medicine. Venture capitalists, private equity firms, and large pharmaceutical companies are increasingly allocating substantial resources to support the development and commercialization of organ-on-chip platforms. This influx of capital is enabling startups and established players alike to accelerate their research and development efforts, expand their technological capabilities, and bring innovative solutions to the market more rapidly.

Market Segmentation:

Segmentation 1: by Application

• Drug Discovery
• Toxicity Testing
• Other Applications

Drug Discovery Segment to Continue Dominating the Organ-on-Chip Market (by Application)

Based on application, the organ-on-chip market has been led by drug discovery, which held a 65.20% share in 2023.

Segmentation 2: by Offering

• Product
• Services

Product Segment to Continue Dominating the Organ-on-Chip Market (by Offering)

Based on offering, the organ-on-chip market has been led by product, which held a 53.94% share in 2023.

Segmentation 3: by Organ Type

• Liver-on-a-Chip
• Kidney-on-a-Chip
• Lung-on-a-Chip
• Heart-on-a-Chip
• Brain-on-a-Chip
• Other Organ-on-Chip

Liver-on-a-Chip Segment to Continue Dominating the Organ-on-Chip Market (by Organ Type)

Based on organ type, the organ-on-chip market has been led by liver-on-a-chip, which held a 28.31% share in 2023.

Segmentation 4: by End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Cosmetic Industry
• Others

Pharmaceutical and Biotechnology Companies Segment to Continue Dominating the Organ-on-Chip Market (by End User)

Based on end user, the organ-on-chip market has been led by pharmaceutical and biotechnology companies, which held a 72.69% share in 2023.

Segmentation 5: by Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest-of-Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest-of-Asia-Pacific
• Latin America
• Middle East and Africa

Rest-of- Asia-Pacific dominated the Asia-Pacific organ-on-chip market in 2023. This region includes fast-growing economies such as Indonesia and Thailand, where increased healthcare spending and governmental research support are beginning to foster market growth. Challenges across these markets include varying regulatory environments and sometimes limited local funding for high-tech research.

Recent Developments in the Organ-on-Chip Market

• In April 2024, CN Bio Innovations Ltd. secured $21 million in the initial closing of its Series B investment round.
• In April 2024, CN Bio Innovations Ltd. was chosen for the NC3R's SensOoChip Challenge, tasked with developing advanced Heart-on-a-Chip technology.
• In January 2024, CN Bio Innovations Ltd. and Altis Biosystems joined forces to develop a human gut/liver in vitro model for advanced absorption, distribution, metabolism, and excretion (ADME) studies.
• In March 2024, InSphero's liver disease team released a groundbreaking peer-reviewed paper in Nature's Scientific Reports, pushing the boundaries of in vitro models in MASH Drug Discovery.

Demand - Drivers and Limitations

Market Demand Drivers:

Increasing Demand for Animal-Free Testing: The growing demand for animal-free testing methods has significantly advanced organ-on-chip technology. These systems, which replicate human organ functions in vitro, are revolutionizing biomedical research and pharmaceutical development. Their capability to mimic human physiology, coupled with long-term cost-efficiency and high-throughput screening, makes them essential tools in modern healthcare and drug discovery. Additionally, the customizable nature of organ-on-chip systems and their alignment with ethical and sustainable practices are expected to further drive innovation and adoption across various research domains.

Increasing Focus on Organ-on-Chip Technology: Organ-on-chip technology has been experiencing a surge in emphasis due to several factors. Ethical concerns surrounding animal testing are driving the search for alternatives, while the potential for improved accuracy in drug development compared to animal models is highly attractive. Additionally, organ-on-chip systems offer potential cost-effectiveness and faster drug discovery through the ability to test multiple compounds simultaneously.

Rising Adoption of Organ-on-Chip (OOC) Technology among Pharmaceutical and Biotechnology Companies: Pharmaceutical and biotechnology companies are increasingly adopting organ-on-chip (OOC) technology due to its transformative potential in drug development and biomedical research. These microfluidic platforms replicate human organ structure and function, providing a more physiologically relevant environment for studying disease mechanisms, drug responses, and toxicity. The growing adoption of OOC technology has been driven by several key factors.

Firstly, OOC platforms offer a more accurate and predictive model compared to traditional cell cultures or animal studies. This enhanced fidelity improves the reliability of preclinical testing, enabling more informed decision-making during drug development. Additionally, OOC systems present a cost-effective alternative to animal studies, reducing the time and resources needed for preclinical research.

Secondly, OOC technology supports high-throughput screening of drug candidates, allowing companies to simultaneously assess multiple compounds in a controlled microenvironment. This capability accelerates the drug discovery process and aids in identifying promising candidates for further development.

Market Challenges:

Limitation of Use Restricted to Preclinical Trials: The use of organ-on-chip (OOC) technology is currently limited primarily to preclinical trials, which could pose a significant constraint on its broader application in clinical settings. While OOC platforms offer remarkable advantages in mimicking human physiology and predicting drug responses, their use is restricted by regulatory and validation challenges. These technologies are yet to be fully integrated into clinical trial phases, as extensive validation and standardization are required to ensure their reliability and reproducibility in a clinical context.

Difficulty in Mimicking Complex Tissues and Organs: One of the significant challenges faced by organ-on-chip (OOC) technology is the difficulty in accurately mimicking complex tissues and organs. While OOC platforms have made impressive strides in replicating simpler organ functions, reproducing the intricate architecture and multifaceted interactions of complex tissues remains a formidable task. The limitations in current microfabrication techniques and biomaterials might hinder the development of fully functional models that precisely emulate the dynamic environment of human organs. Additionally, achieving the integration of multiple cell types and ensuring their long-term viability and functionality within the chip adds another layer of complexity.

Market Opportunities:

Development of Multi-Organ-on-Chip Systems: The development of multi-organ-on-chip (OOC) systems marks a significant stride in biomedical research and drug development. These systems integrate various organ-on-chip platforms into a unified device, enabling researchers to replicate the intricate interactions between different organs and study complex physiological responses more comprehensively. By simulating the interconnectedness and communication between organs, multi-organ-on-chip systems offer a more realistic model of human biology than single-organ models.

Organ-on-Chip Technologies to Hasten Transition to Personalized Medicine: Organ-on-chip (OOC) technologies represent a transformative approach in biomedical research that is expected to hasten the transition to personalized medicine. These innovative platforms replicate the microenvironments and functionalities of human organs, allowing for the study of organ-level responses in a controlled setting. By incorporating patient-derived cells or tissues into OOC models, researchers can assess individualized responses to treatments and therapies, paving the way for tailored healthcare solutions. OOC technologies offer several advantages for personalized medicine, including the ability to mimic disease states, evaluate drug efficacy and toxicity with higher accuracy, and optimize treatment strategies based on patient-specific characteristics. Furthermore, OOC platforms enable researchers to explore complex disease mechanisms, identify biomarkers, and develop targeted therapies for precision medicine approaches. As these technologies continue to evolve and gain traction, they hold immense potential to revolutionize healthcare by providing more effective, efficient, and patient-centered solutions.

How can this report add value to an organization?

Product/Innovation Strategy: The global organ-on-chip market has been extensively segmented based on various categories, such as technology, products, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Partnerships, alliances, and collaborations accounted for the maximum number of key developments, i.e., nearly 30.77% of the total developments in the global organ-on-chip market were between January 2021 and April 2024.

Competitive Strategy: The global organ-on-chip market has numerous established players with product portfolios. Key players in the global organ-on-chip market analyzed and profiled in the study involve established players offering organ-on-chip.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• Detailed secondary research was performed to ensure maximum coverage of manufacturers/suppliers operational in a country.
• Exact revenue information, up to a certain extent, was extracted for each company from secondary sources and databases. The revenues specific to the application, offering, organ type, and region were then estimated for each market player based on fact-based proxy indicators as well as primary inputs.
• The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study on organ-on-chip.
• The market contribution of the organ-on-chip products anticipated to be launched in the future has been calculated based on historical analysis. This analysis has been supported by proxy factors such as the innovation scale of the companies, the status of funding, collaborations, customer base, and patent scenario.
• The scope of availability of organ-on-chip products and technologies in a particular region has been assessed based on a comprehensive analysis of companies' prospects, regional end-user perception, and other factors impacting the launch of organ-on-chip in that region.
• The base year considered for the calculation of the market size is 2023. A historical year analysis has been done for the period FY2021-FY2022. The market size has been estimated for FY2023 and projected for the period FY2024-FY2033.
• Revenues of the companies have been referenced from their annual reports for FY2020-FY2023. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, product approval status, market collaborations, and operational history.
• Regional distribution of the market revenue has been estimated based on the companies in each region and the adoption rate of organ-on-chip. All the numbers have been adjusted to a single digit after the decimal for better presentation in the report. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. The CAGR has been calculated for the period 2024-2033.
• The market has been mapped based on the available organ-on-chip offerings. All the key companies with significant offerings in this field have been considered and profiled in this report.
• Market strategies and developments of key players have been considered for the calculation of the potential of the market in the forecast period.

Primary Research:

The primary sources involve industry experts in the organ-on-chip market, including the market players offering organ-on-chip products. Resources such as CXOs, vice presidents, product managers, directors, territory managers, and business development have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings for organ-on-chip
• Understanding the competitive landscape and business model
• Current and proposed production values of a product by market players
• Validation of the numbers of the different segments of the market in focus
• Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• European Medicines Agency (EMA), Food and Drug Administration (FDA), Frontiers, World Health Organization (WHO), National Center for Advancing Translational Sciences (NCATS), and National Center for Biotechnology Information (NCBI), among others
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their portfolios
• Gold standard magazines, journals, whitepapers, press releases, and news articles
• Databases

The key data points taken from the secondary sources include:

• Segmentation and percentage share estimates
• Companies' and countries' understanding and data for market value estimation
• Key industry/market trends
• Developments among top players
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, type portfolio, and market penetration.

Some prominent names in the global organ-on-chip market include:

• Emulate, Inc.
• Mimetas B.V.
• Kirkstall Ltd.
• Numa Biosciences
• AxoSim
• BICO Group AB
• CN Bio Innovations Ltd.
• TissUse GmbH
• InSphero
• The Charles Stark Draper Laboratory, Inc.
• Obatala Sciences

Table of Contents

Executive Summary

Scope and Definition

1 Markets

• 1.1 Trends: Current and Future Impact Assessment
  • 1.1.1 Increasing Partnerships among Players
  • 1.1.2 Increasing Investment and Funding for Organ-on-Chip Technologies
• 1.2 R&D Review
  • 1.2.1 Patent Filing Trend (by Year, Country)
• 1.3 Supply Chain Overview
  • 1.3.1 Value Chain Analysis
  • 1.3.2 Market Map
• 1.4 Regulatory Landscape
  • 1.4.1 Regulatory Framework in the U.S.
  • 1.4.2 Regulatory Framework in Europe
  • 1.4.3 Regulatory Framework in Japan
  • 1.4.4 Regulatory Framework in China
  • 1.4.5 Regulatory Framework in Other Countries
    • 1.4.5.1 Regulatory Framework in India
    • 1.4.5.2 Regulatory Framework in Latin America
    • 1.4.5.3 Regulatory Framework in the Middle East and Africa
• 1.5 Market Dynamics: Overview
  • 1.5.1 Market Drivers
    • 1.5.1.1 Increasing Demand for Animal-Free Testing
    • 1.5.1.2 Increasing Focus on Organ-on-Chip Technology
    • 1.5.1.3 Rising Adoption of Organ-on-Chip (OOC) Technology among Pharmaceutical and Biotechnology Companies
    • 1.5.1.4 Ethical Considerations Surrounding the Utilization of Animal Models in Drug Development
  • 1.5.2 Market Challenges
    • 1.5.2.1 Limitation of Use Restricted to Preclinical Trials
    • 1.5.2.2 Difficulty in Mimicking Complex Tissues and Organs
  • 1.5.3 Market Opportunities
    • 1.5.3.1 Development of Multi-Organ-on-Chip Systems
    • 1.5.3.2 Organ-on-Chip Technologies to Hasten Transition to Personalized Medicine

2 Application

• 2.1 Application Segmentation
• 2.2 Application Summary
• 2.3 Global Organ-on-Chip Market (by Application)
  • 2.3.1 Drug Discovery
  • 2.3.2 Toxicity Testing
  • 2.3.3 Other Application
• 2.4 Global Organ-on-Chip Market (by End User)
  • 2.4.1 Pharmaceutical and Biotechnology Companies
  • 2.4.2 Academic and Research Institutes
  • 2.4.3 Cosmetic Industry
  • 2.4.4 Others

3 Products

• 3.1 Product Segmentation
• 3.2 Product Summary
• 3.3 Global Organ-on-Chip Market (by Offering)
  • 3.3.1 Product
  • 3.3.2 Services
• 3.4 Global Organ-on-Chip Market (by Organ Type)
  • 3.4.1 Liver-on-a-Chip
  • 3.4.2 Kidney-on-a-Chip
  • 3.4.3 Lung-on-a-Chip
  • 3.4.4 Brain-on-a-Chip
  • 3.4.5 Heart-on-a-Chip
  • 3.4.6 Other Organ-on-Chip

4 Regions

• 4.1 Regional Summary
• 4.2 North America
  • 4.2.1 Regional Overview
  • 4.2.2 Driving Factors for Market Growth
  • 4.2.3 Factors Challenging the Market
    • 4.2.3.1 Application
    • 4.2.3.2 Product
  • 4.2.4 U.S.
  • 4.2.5 Canada
• 4.3 Europe
  • 4.3.1 Regional Overview
  • 4.3.2 Driving Factors for Market Growth
  • 4.3.3 Factors Challenging the Market
    • 4.3.3.1 Application
    • 4.3.3.2 Product
  • 4.3.4 U.K.
  • 4.3.5 Germany
  • 4.3.6 France
  • 4.3.7 Italy
  • 4.3.8 Spain
  • 4.3.9 Rest-of-Europe
• 4.4 Asia-Pacific
  • 4.4.1 Regional Overview
  • 4.4.2 Driving Factors for Market Growth
  • 4.4.3 Factors Challenging the Market
    • 4.4.3.1 Application
    • 4.4.3.2 Product
  • 4.4.4 China
  • 4.4.5 Japan
  • 4.4.6 India
  • 4.4.7 South Korea
  • 4.4.8 Rest-of-Asia-Pacific
• 4.5 Latin America
  • 4.5.1 Regional Overview
  • 4.5.2 Driving Factors for Market Growth
  • 4.5.3 Factors Challenging the Market
    • 4.5.3.1 Application
    • 4.5.3.2 Product
  • 4.5.4 Brazil
  • 4.5.5 Mexico
  • 4.5.6 Rest-of-Latin America
• 4.6 Middle East and Africa
  • 4.6.1 Regional Overview
  • 4.6.2 Driving Factors for Market Growth
  • 4.6.3 Factors Challenging the Market
    • 4.6.3.1 Application
    • 4.6.3.2 Product

5 Markets - Competitive Benchmarking & Company Profiles

• 5.1 Next Frontiers
  • 5.1.1 Emulate, Inc.
    • 5.1.1.1 Overview
    • 5.1.1.2 Top Products
    • 5.1.1.3 Top Competitors
    • 5.1.1.4 Key Personnel
    • 5.1.1.5 Analyst View
  • 5.1.2 Mimetas B.V.
    • 5.1.2.1 Overview
    • 5.1.2.2 Top Products
    • 5.1.2.3 Top Competitors
    • 5.1.2.4 Key Personnel
    • 5.1.2.5 Analyst View
  • 5.1.3 Kirkstall Ltd.
    • 5.1.3.1 Overview
    • 5.1.3.2 Top Products
    • 5.1.3.3 Top Competitors
    • 5.1.3.4 Key Personnel
    • 5.1.3.5 Analyst View
  • 5.1.4 Numa BioSciences
    • 5.1.4.1 Overview
    • 5.1.4.2 Top Products
    • 5.1.4.3 Top Competitors
    • 5.1.4.4 Key Personnel
    • 5.1.4.5 Analyst View
  • 5.1.5 AxoSim
    • 5.1.5.1 Overview
    • 5.1.5.2 Top Products
    • 5.1.5.3 Top Competitors
    • 5.1.5.4 Key Personnel
    • 5.1.5.5 Analyst View
  • 5.1.6 BICO Group AB
    • 5.1.6.1 Overview
    • 5.1.6.2 Top Products
    • 5.1.6.3 Top Competitors
    • 5.1.6.4 Key Personnel
    • 5.1.6.5 Analyst View
  • 5.1.7 CN Bio Innovations Ltd.
    • 5.1.7.1 Overview
    • 5.1.7.2 Top Products
    • 5.1.7.3 Top Competitors
    • 5.1.7.4 Key Personnel
    • 5.1.7.5 Analyst View
  • 5.1.8 SynVivo, Inc.
    • 5.1.8.1 Overview
    • 5.1.8.2 Top Products
    • 5.1.8.3 Top Competitors
    • 5.1.8.4 Key Personnel
    • 5.1.8.5 Analyst View
  • 5.1.9 BEOnchip
    • 5.1.9.1 Overview
    • 5.1.9.2 Top Products
    • 5.1.9.3 Top Competitors
    • 5.1.9.4 Key Personnel
    • 5.1.9.5 Analyst View
  • 5.1.10 The Charles Stark Draper Laboratory, Inc.
    • 5.1.10.1 Overview
    • 5.1.10.2 Top Products
    • 5.1.10.3 Top Competitors
    • 5.1.10.4 Key Personnel
    • 5.1.10.5 Analyst View
  • 5.1.11 TissUse GmbH
    • 5.1.11.1 Overview
    • 5.1.11.2 Top Products
    • 5.1.11.3 Top Competitors
    • 5.1.11.4 Key Personnel
    • 5.1.11.5 Analyst View
  • 5.1.12 InSphero
    • 5.1.12.1 Overview
    • 5.1.12.2 Top Products
    • 5.1.12.3 Top Competitors
    • 5.1.12.4 Key Personnel
    • 5.1.12.5 Analyst View
  • 5.1.13 Obatala Sciences
    • 5.1.13.1 Overview
    • 5.1.13.2 Top Products
    • 5.1.13.3 Top Competitors
    • 5.1.13.4 Key Personnel
    • 5.1.13.5 Analyst View
  • 5.1.14 Hesperos, Inc.
    • 5.1.14.1 Overview
    • 5.1.14.2 Top Products
    • 5.1.14.3 Top Competitors
    • 5.1.14.4 Key Personnel
    • 5.1.14.5 Analyst View
  • 5.1.15 Cherry Biotech
    • 5.1.15.1 Overview
    • 5.1.15.2 Top Products
    • 5.1.15.3 Top Competitors
    • 5.1.15.4 Key Personnel
    • 5.1.15.5 Analyst View

6 Research Methodology

• 6.1 Data Sources
  • 6.1.1 Primary Data Sources
  • 6.1.2 Secondary Data Sources
  • 6.1.3 Data Triangulation
• 6.2 Market Estimation and Forecast